ERBB2 and breast cancer: Similarly, Tini et al. [23], in two cohorts of breast cancer women treated with anthracyclines and anti-HER2, concluded that patients classified at medium–high risk using the HFA-ICOS score were not associated with the occurrence of cardiac dysfunction.